After years of construction and millions of dollars, the long-awaited CV Link is officially open — a 40-mile path stretching ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

Semaglutide therapy was associated with higher likelihood of passing low-risk cardiovascular thresholds among patients with ...

Q3 2025 Management View CEO Joseph Dowling opened the call by stating, "We are pleased with our progress as we move closer to ...

Oral semaglutide 25 mg was associated with improved glycemic parameters and cardiovascular risk across weight loss categories ...

Following the approvals from exchanges, Tata Motors had informed in an exchange filing this week that its CV business will ...